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Summary
Introduction PAD medical therapy has a number of limitations. RLX showed promises in 
experimental model mainly through NO release. Our study is the first to evaluate the efficacy 
and safety of RLX in PAD. 
Materials-Methods eligible PAD La fontaine IIa-IIb patients were randomized in 2 groups. 
Group A was treated with physical therapy plus oral pRLX, 20 ug b.i.d for 12 weeks, group B 
received physical therapy alone. Pain Free Walking Distance (PFWD) and Maximum Walking 
Distance (MWD) at 3 and 12 wks and at follow up 3 months after treatment interruption were 
performed. 
Results The percentage increases of PFWD in group B were 23±9, 65±17, and 35±4 respectively 
at 3 and at 12 weeks. and 3 months after termination. In Group A showed significantly higher 
percentage increases: 74±16 p<0.01, 168±28 p<0.001, and 122±15 p<0.001 at the corresponding 
time points. The percentage increases of MWD in the B group were 29±7, 55±10 and 54±8 at 
the above time points, while in the A group were 55±10 p<0.001, and 99±12 p<0.001. The RLX 
patients referred a better physical and mental status. No adverse events during or after the 
treatment were recorded. 
Comment-RLX resulted very effective in PAD. Our results may suggest that the observed func-
tional benefits should come not only from hemodynamic improvement but also from positive 
vascular remodeling.
Introduction
Peripheral arterial disease (PAD) is caused by chronic arterial occlusive disease of 
the lower extremities caused by atherosclerosis. PAD may cause intermittent claudi-
cation which is pain or weakness with walking that is relieved with rest. Muscle pain 
or weakness after exercise occurs distal to the arterial obstruction. Since the super-
ficial femoral and popliteal arteries are most commonly affected by atherosclerosis, 
the pain of intermittent claudication is most commonly localized to the calf . Meas-
urement of ankle and brachial artery systolic blood pressures using a Doppler steth-
oscope and blood pressure cuffs allows calculation of the ankle-brachial index (ABI) 
which is normally 0.9 to 1.2. An ABI of less than 0.90 is 95% sensitive and 99% specif-
ic for the diagnosis of PAD. The lower the ABI, the more severe the restriction of arte-
rial blood flow, and the more serious the ischemia. The prevalence of PAD increases 
with age. Schroll and Munck reported that the prevalence of PAD was 16% in men 
and 13% in women aged 60 years [1]. Treatment of chronic PAD is mainly based on 
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cholesterol and blood pressure control, antiaggregants such as acetilsalicilic acid or 
Clopidogrel. Cilostazol has been documented in numerous trials to improve exercise 
capacity in patients with intermittent claudication and in a dose of 100 mg twice dai-
ly, was shown to be superior to both placebo and pentoxifylline [2]. Another option 
is exercise for intermittent claudication. Exercise rehabilitation programs have been 
shown to increase walking distance in persons with intermittent claudication through 
improvements in peripheral circulation, walking economy, and cardiopulmonary 
function [3-4]. The optimal exercise program for improving claudication pain distance 
in persons with PAD uses intermittent walking to near-maximal pain during a pro-
gram of at least 6 months [5]. Supervised exercise training is recommended for a min-
imum of 30-45 min in sessions performed at least 3 times per week for a minimum of 
12 weeks and preferably for 6 months or longer.
Since there is room for better treatment option we investigated the role of Relax-
in (RLX) an hormone that belongs to the relaxin hormone super-family, which in 
humans includes 3 RLX molecules and 4insulin-like peptides. Of these, luteal RLX 
is the main circulating form in animals and man. RLX, formerly known for its effects 
on reproduction and pregnancy, has been demonstrated to act on numerous other 
targets, including the cardiovascular, central and peripheral nervous, respiratory, teg-
ument, excretory and digestive systems. Most of these effects have been studied in 
animal models, but there is compelling evidence that RLX also acts in the human. 
RLX may be a novel therapy in cardiovascular disease because it induces microves-
sel dilation, blood flow increase, platelet inhibition and neo-angiogenesis, mainly 
through nitric oxide release. This article report the first clinical experience with puri-
fied preparation of oral porcine RLX (pRLX) that is now available and fits well for 
chronic use.
AIM OF THE STUDY
The aim of the study was to evaluate the safety and the efficacy of oral porcine 
relaxin in adjunct to physical exercise in patients with chronic peripheral artery dis-
ease la fontaine stage IIA-IIB in comparison to physical exercise alone. We investigat-
ed the effect on the two main parameters of walking capability: the pain free walking 
distance and the maximum walking distance.
DESIGN OF THE STUDY
This is a randomized, open label, single center, controlled trial comparing the effi-
cacy and safety of oral porcine relaxin in adjunct to physical exercise versus physical 
exercise alone. 
POPULATION OF THE STUDY
Consecutive patients both male and female affected by PAD stage IIa-IIb who 
gave informed consent to the participation to the study and that fulfill all the follow-
ing inclusion criteria with no exclusion criteria:
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INCLUSION CRITERIA
1) Presence of claudicatio intermittens that relieves few minutes after stopping activity. 
2) Patients of age ranging from 18 to 85 years.
3) Stable symptoms of intermittens claudicatio for at least one month before enrollment
4) Documented PAD by echo-color doppler or conventional angiography 
5) Subjects judged affordable that accept all the appointments for control and proto-
col visit 
6) The subject or its legal tutor have to sign the informed consent
7) Female can partecipate only if potentially not fertile : 
a) women potentially not fertile ( menopause from more than one year or surgi-
cally sterile 
b) women potentially fertile for whom pregnancy is excluded by an urinary test 
in the screening visit and that ensure an adequate contraception during the 
study period
Exclusion criteria 
1) Patients with PAD causing ischemic pain at rest or trophic lesions (patients stage 
III e IV) according to la Fontaine classification.
2) Patients in whom endovascular procedure is the treatment of choice (in example 
single stenosis of the common iliac artery or of the external iliac artery < 3cm) 
3) one of the following contraindications to physical exercise (severe coronary disease, 
severe kidney failure, patients hemodinamically unstable, need of continuous oxy-
gen therapy for chronic respiratory insufficiency, orthopedic diseases that limits 
walking capability, recent myocardial infarction, hemiplegy, uncontrolled hyper-
tension)
4) Patients with a medical history for allergy to drugs 
5) Patients with an history of alcohol abuse or suspect alcohol or drug addiction in 
the former two years 
6) Subject with low compliance to therapy assumption or that at judgment of the 
investigator should be at risk of low compliance 
7) Sever gastrointestinal disease that could interfere with relaxin absorption 
8) women in pregnancy or lactation. 
9) Women potentially fertile with no adequate contraception 
10) significant alteration of the laboratory test 
11) Subjects that participated to another trial in the month before the screening visit 
or that plan to be enrolled to a protocol that use an experimental drug or devices 
Material and methods
A total of 18 Consecutive eligible patients attending to Prosperius Institute from 
March 2010 to 2011 were evaluated, 2 were excluded 1 for an history of allergy to 
medication and another for low compliance. Sixteen patients 14 males and 2 females 
(mean age 67,8) were randomised in two groups. 8 patients in Group A received 
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physical exercise alone while 8 patients of group B received oral porcine relaxin at 20 
mcg every 12 hours in adjunct to physical exercise for 12 weeks.
Physical exercise was conducted on tapis roulant at 3,2 km/hr speed at zero 
degree incline. 
Exercise lasted from 30 to 45 minutes for session and was repeated three times a 
week 
All Patients underwent EKG and echocolordoppler of the artery of the lower 
limbs and ankle brachial index evaluation at baseline. Patients had also blood taken 
for sampling for complete blood count, renal function, hepatic function coagulation 
elettrolyte the echodoppler of the artery of the lower limbs was repeated at 12 and a 
24 weeks. Blood samples were also taken to determine the same parameters of base-
line at Visit 1 (after 3 weeks) and at visit 2 (after 12 weeks).
Endpoints:
Primary endpoints:
Effect of treatment on pain free walking distance and on maximum walking dis-
tance. Treadmill test for evaluation of PFWD and of MWD was executed at 2.5km/
hr speed, starting from 6% inclination and increasing 2 % inclination every 2 minutes. 
This test was repeated at 3-12 and 24 weeks
Pain free walking distance was determined as the distance where the pain 
began. Maximum walking distance was calculated as the maximum distance that 
the patients could walk. Stop was determined by pain at maximum entity (of a scale 
from 1 to 5) or by dyspnea, or tachycardia or intense fatigue
Secondary endpoints
Variation of ankle brachial index 
Valuation of treatment satisfaction questionnaire modified (TSQM) for patients 
treated with relaxin variation in renal and hepatic function or glycosilated hemoglobin. 
Statistical analysis
Differences were calculated as percent variation of individual initial values. was 
done by Student’s test and two-way ANOVA,
The results were calculated as percentage variation of individual initial values. 
Statistical analysis was done by Student’s t test and two-way ANOVA followed by 
Bonferroni’s multiple comparison test. 
OUTCOME MEASURES 
The primary objective of our study was to evaluate the improvement induced by 
oral porcine RLX treatment on Pain-Free Walking Distance (PFWD) and of Maximum 
Walking Distance (MWD) registered at a follow-up of 3 and 12 weeks and 3 months. 
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RESULTS PFWD
Both groups improved during and after the trial. The percentage increases of 
PFWD in patients assigned to physical exercise were 23 ± 9%, 65 ± 17%, and 35 ± 4 % 
respectively at 3 and a 12 weeks and 3 months after placebo/physical exercise termi-
nation. In comparison, patients treated with oral porcine relaxin group showed signif-
icantly higher percentage increases 74 ± 16 p <0.01, 168 ± 28 p < 0.001, and 122 ±15 p 
< 0.001 at the corresponding time points. 
RESULTS MWD
Similarly, the percentage increases of MWD in the group assigned to physical 
exercise were 29±7, 55±10 and 54±8 at 3-12 and 24 weeks, while in the group receiv-
ing oral porcine relaxin were 55±10 p<0.001, and 99±12 p<0.001. The therapeutical 
action of pRLX appeared very soon and lasted up to 3 months after withdrawal. The 
RLX patients referred a better physical and mental status. No adverse events during 
or after the treatment were recorded. Of interest 6 of the 8 patients assigned to oral 
relaxin stopped their exercise for dispnea or tachycardia and not for maximum toler-
ated pain
ADDITIONAL RESULTS
Variations on ankle-brachial index (Winsor Index) were also evaluated.
Possible side effects of the treatment were carefully monitored. 
Treatment satisfaction questionnaire for medication (TSqM) was done at the end 
of treatment by all patients. Blood assays were carried out to monitor routine blood 
parameters, kidney and liver functions, and glycated hemoglobin. 
Treatment satisfaction to oral porcine RLX was very high, 81,25% regarding effi-
cacy, 100% considering tolerability, 78,65% on the easiness of use and 95,25% as a 
whole. 
No changes were observed in ankle-brachial index between the groups at any test 
time (before treatment: physical exercise, 0,81; physical exercise + oral porcine relaxin, 
0,82. The same parameters evaluated after treatment: physical treatment, 0,68; phys-
ical treatment + oral porcine relaxin, 0,67. No effects were observed in glycemic sta-
tus: before and after the treatment, glycated hemoglobin was 6,27% and 6,36% in the 
physical exercise group, 6,70 and 6,77 in the physical exercise plus oral porcine relax-
in group. No changes related to the treatment were observed in routine blood tests as 
well as on the markers of liver and kidney function. No adverse events were reported 
during treatment and during the follow-up period
Discussion 
PAD is a chronic disease carrying an higher risk of cardiovascular complications 
and death than healthy population. On the other hand PAD at stage II is a disease 
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with a slow progression and somewhat stable, therefore patients often are not wor-
ried by the disease itself. Symptoms are characterized by pain during walking that 
can be localized also in the buttocks, hips, thighs, or the inferior back muscles Ather-
osclerotic obstruction of the distal aorta and its bifurcation into the two iliac arteries. 
Criqui et al. showed that the prevalence of PAD was 5.6% in persons aged 38 to 59 
years, 15.9% in persons aged 60 to 69 years old, and 33.8% in persons aged 70 to 82 
years old [6]. In the Cardiovascular Health Study, PAD was present in 13.9% of 2,214 
men aged ≥ 65 years and in 11.4% of 2,870 women aged ≥ 65 years without cardio-
vascular disease [7]. The ACCP recently published guidelines for antithrombotic drug 
therapies for primary and secondary prevention of cardiovascular disease as well as 
for the relief of lower-extremity symptoms in persons with chronic peripheral arterial 
disease (PAD) stage IIa-IIb. [8]. For secondary prevention of cardiovascular disease 
in patients with symptomatic PAD (including patients before and after peripheral 
arterial bypass surgery or percutaneous transluminal angioplasty), the usual therapy 
is long-term aspirin (75-100 mg/d) or clopidogrel (75 mg/d) (Grade 1A). Warfarin 
plus aspirin in patients with symptomatic PAD was not recommended (Grade 1B). 
For patients with refractory claudication despite exercise therapy and smoking cessa-
tion, the s addition of cilostazol (100 mg bid) to aspirin (75-100 mg/d) or clopidogrel 
(75 mg/d) (Grade 2C) was suggested. Two drugs, pentoxifylline and cilostazol, have 
been approved by the United States Food and Drug Administration for symptomatic 
treatment of intermittent claudication. 
Scientific awareness of the existence of relaxin (RLX) dates back to 1926, when 
Frederick Hisaw found that the serum from pregnant guinea pigs or rabbits into vir-
gin guinea pigs contained a hormone-like substance which induced relaxation of the 
interpubic ligament [9], has been long considered pertinent to reproduction, based on 
early studies demonstrating its ability to promote elongation of the interpubic liga-
ment in mammals [10], Four years later, the peptide substance held responsible for 
this effect was purified and identified from pregnant sow luteal extracts and desig-
nated relaxin. RLX has a molecular weight of about 6,000 Dalton and consists of 2 
chains, termed A and B, which are covalently linked by 2 interchain disulfide bonds 
with a further intra-disulfide bond in the A chain Extra-luteal sources of H2 peptide 
H1 RLX have been detected in a few reproductive tissues including the decidua, pla-
centa and prostate Exhaustive information on this issue is available on previously 
published reviews [11-12]. The notion that RLX is a cardiovascular hormone dates 
back to the late 1950s, when an impure porcine RLX preparation, injected to patients 
suffering for peripheral vascular diseases and Raynaud’s syndrome, was shown to 
cause a dramatic, albeit transient, amelioration of symptoms and signs of ischemia 
[13]. In some patients who also suffered for ischemic heart disease, RLX treatment led 
to the reduction of the daily glyceryl trinitrate requirements. This observation clear-
ly suggests that RLX has a direct, dilatory effect on peripheral and coronary vascu-
lature. Recognition of the blood vessels as specific RLX targets came from the iden-
tification of RLX binding sites/receptors on cells of the vascular wall [14-16 ]. RLX 
promotes vasodilatation in reproductive organs, such as the uterus [17, 18] and the 
mammary gland [19], as well as in non-reproductive targets, including mesocaecum 
[20], kidney [21], liver [22], lung [23] and heart [24,25]. Vasodilatation appears as a 
physiological effect of RLX since it is fully manifested at hormone concentrations 
which are in the nanomolar range, similar to the RLX blood levels of normal human 
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pregnancy. RLX is extremely potent as a vasorelaxant: in the isolated, perfused rat 
and guinea pig heart, the dose-dependent increase in coronary flow induced by RLX 
is significantly higher than that obtained with similar doses of typical vasodilatatory 
agents such as acetylcholine or sodium nitroprusside. This latter concept indirectly 
suggested that these effects of RLX would be mediated by mechanisms involving a 
potent vascular effector and, once again, NO appeared as the perfect candidate. This 
was the first clinical aiming to evidence the efficacy and safety of oral porcine RLX in 
patients with chronic ischemic PAD stage la Fontaine IIa-IIb. Results indicate a signif-
icant additive effect in adjunct to exercise therapy. These results were obtained with-
out the presence of any adverse event related to the treatment. Of note the amelio-
ration was present from the first three weeks and was sustained over 12 weeks after 
stopping treatment. Although preliminary for the limited number of treated patients, 
indeed, the results suggest that oral porcine RLX given to patients with chronic PAD 
at the described administration regimen is capable of inducing a prompt and signifi-
cant amelioration of the primary outcome parameters of walking capability, associat-
ed with an improvement of the patients’ general conditions. This increase in walking 
capability was not due to the reopening of the major artery, in fact the ankle brachi-
al index was not modified. Of interest, the treatment resulted safe and well tolerat-
ed by the patients, who subjectively reported high satisfaction and reported an ease 
of administration and a lack of negative effect. In our opinion these results strongly 
encourage further clinical research on the effect of relaxin on cardiovascular disease 
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